The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization ofBIMEL

Oncogene

Volumn 28, Issue 16, 2009, Pages 1864-1874

  Guo, Y ^a   Schoell, M C ^b,c   Freeman, R S ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; BI MEL; Protein stability; Re nal cell carcinoma; VHL

Indexed keywords

BIM PROTEIN; ETOPOSIDE; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BIM EL; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RNA INTERFERENCE; SENSITIZATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ULTRAVIOLET RADIATION; WILD TYPE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOPRECIPITATION; KIDNEY NEOPLASMS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; UBIQUITIN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 67349265185     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.35     Document Type: Article

References (42)

1. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F et al. (1999). Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738.
2. Bruick RK, McKnight SL. (2001). A conserved family of prolyl-4- hydroxylases that modify HIF. Science 294: 1337-1340.
3. Cohen HT. (1999). Advances in the molecular basis of renal neoplasia. Curr Opin Nephrol Hypertens 8: 325-331.
4. Devarajan P, De Leon M, Talasazan F, Schoenfeld AR, Davidowitz EJ, Burk RD. (2001). The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. 1 Biol Chem 276: 40599-10605.
5. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
6. Ewings KE, Wiggins CM, Cook SJ. (2007). Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 6: 2236-2240.
7. Frew IJ, Krek W. (2008). pVHL: a multipurpose adaptor protein. Sci Signal 1: pe30.
8. Fu J, Menzies K, Freeman RS, Taubman MB. (2007). EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J Biol Chem 282: 12410-12418.
9. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90.
10. Gorospe M, Egan JM, Zbar B, Lerman M, Geil L, Kuzmin I et al. (1999). Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 19: 1289-1300.
11. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. (2003). Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 5: 64-70.
12. Iliopoulos O, Kibel A, Gray S, Kaelin Jr WG. (1995). Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
13. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M et al. (2001). HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science 292: 464-468.
14. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW et al. (1999). Identification of the von Hippel-lindau tumor- suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acaä Sci USA 96: 12436-12441.
15. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by 02-regulated prolyl hydroxylation. Science 292: 468-172.
16. Kaelin WG. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682.
17. Kim M, Yan Y, Lee K, Sgagias M, Cowan KH. (2004). Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-0 renal cell carcinoma cells and regresses tumor growth of 786-0 cells in nude mouse. Biochem Biophys Res Commun 320: 945-950.
18. Kurban G, Duplan E, Ramlal N, Hudon V, Sado Y, Ninomiya Y et al. (2008). Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated col- lagen IV alpha 2. Oncogene 27: 1004-1012.
19. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP et al. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
20. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. (2003). Activation of the ERK1/2 signaling pathway promotes phosphor- ylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816.
21. Ley R, Ewings KE, Hadfield K, Cook SJ. (2005). Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 12: 1008-1014.
22. Lipscomb EA, Sarmiere PD, Crowder RJ, Freeman RS. (1999). Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons. / Neurochem 73: 429-432.
23. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW et al. (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18: 732-741.
24. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
25. Nyhan MJ, O'Sullivan GC, McKenna SL. (2008). Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 36: 472-178.
26. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S et al. (1998). Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-395.
27. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M et al. (2001). The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. / Biol Chem 276: 43611-43617.
28. Qi H, Ohh M. (2003). The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor- induced cytotoxicity by suppressing the nuclear factor-kappaB- dependent antiapoptotic pathway. Cancer Res 63: 7076-7080.
29. Qi XJ, Wildey GM, Howe PH. (2006). Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281: 813-823.
30. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. (2006). p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22: 395-405.
31. Schermer B, Ghenoiu C, Bartram M, Muller RU, Kotsis F, Hohne M et al. (2006). The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth. / Cell Biol 175: 547-554.
32. Schoenfeld AR, Parris T, Eisenberger A, Davidowitz EJ, De Leon M, Talasazan F et al. (2000). The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 19: 5851-5857.
33. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
34. Stebbins CE, Kaelin Jr WG, Pavletich NP. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455-461.
35. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA et al. (2005). Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5: 57.
36. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. (2007). Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
37. Xie L, Johnson RS, Freeman RS. (2005). Inhibition of NGF deprivation-induced death by low oxygen involves suppression of BIM(EL) and activation of HIF-1. / Cell Biol 168: 911-920.
38. Yagoda A, Abi-Rached B, Petrylak D. (1995). Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22: 42-60.
39. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X et al. (2007). pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27.
40. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S et al. (2007). Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26: 7038-7048.
41. Zhang W, Cheng GZ, Gong J, Hermanto U, Zong CS, Chan J et al. (2008). RACK1 and CIS Mediate the Degradation of BimEL in Cancer Cells. J Biol Chem 283: 16416-16426.
42. Zhou MI, Wang H, Ross JJ, Kuzmin I, Xu C, Cohen HT. (2002). The von Hippel-Lindau tumor suppressor stabilizes novel plant homeo- domain protein Jade-1. / Biol Chem 211: 39887-39898.